Clinical Trial

CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The main objective of this national study is to evaluate the virological success of long-acting antiretroviral therapy combining cabotegravir and lenacapavir. The study involves patients who have been receiving this treatment for one year or those for whom the physician decides to initiate it. It also aims to evaluate the tolerability of the treatment and changes in the participants' immunovirological profile during follow-up.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-03.
Trial Details
NCT Number NCT07402044
Lead Sponsor Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Collaborators: INSERM UMR S 1136, ANRS, Emerging Infectious Diseases
Conditions CABOTEGRAVIR, LENACAPAVIR
Enrollment 50 participants
Start Date 2026-03-15
Primary Completion 2028-03-15 (estimated)
Study Completion 2028-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-03-27